CTLA4 and cancer: Recently, immune checkpoint blockade has become a promising strategy for cancer treatment, with monoclonal antibodies targeting programmed cell death protein 1 (PD- 1), PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).